Baker Brothers Advisors - Q3 2023 holdings

$17.4 Billion is the total value of Baker Brothers Advisors's 101 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 22.4% .

 Value Shares↓ Weighting
SGEN  Seagen Inc.$9,452,165,468
+10.2%
44,554,1620.0%54.48%
+9.8%
BGNE  BeiGene, Ltd.sponsored adr$2,098,884,503
+0.9%
11,668,8970.0%12.10%
+0.5%
INCY BuyIncyte Corporation$2,090,035,758
-7.2%
36,178,566
+0.0%
12.05%
-7.6%
ACAD  ACADIA Pharmaceuticals Inc.$893,298,514
-13.0%
42,864,6120.0%5.15%
-13.3%
BMRN  BioMarin Pharmaceutical Inc.$337,130,743
+2.1%
3,810,2480.0%1.94%
+1.7%
MDGL  Madrigal Pharmaceuticals, Inc.$225,648,303
-36.8%
1,545,1130.0%1.30%
-37.1%
RYTM BuyRhythm Pharmaceuticals, Inc.$153,651,351
+43.4%
6,702,349
+3.1%
0.89%
+42.9%
BuyRoivant Sciences Ltd.$138,725,357
+46.0%
11,877,171
+26.0%
0.80%
+45.5%
IMCR  Immunocore Holdings plcads$130,825,939
-13.4%
2,520,7310.0%0.75%
-13.8%
 Invitae Corporationnote 1.5% 4/1/2028$130,372,500
-3.4%
300,000,0000.0%0.75%
-3.8%
AKRO  Akero Therapeutics, Inc.$119,792,559
+8.3%
2,368,3780.0%0.69%
+7.8%
ABCL BuyAbCellera Biologics Inc.$95,511,286
-10.1%
20,763,323
+26.2%
0.55%
-10.6%
BCRX  BioCryst Pharmaceuticals, Inc.$89,992,591
+0.6%
12,710,8180.0%0.52%
+0.2%
REPL  Replimune Group, Inc.$78,334,371
-26.3%
4,578,2800.0%0.45%
-26.7%
 Entrada Therapeutics, Inc.$76,879,940
+4.4%
4,865,8190.0%0.44%
+4.0%
RVMD  Revolution Medicines, Inc.$74,500,526
+3.5%
2,691,4930.0%0.43%
+2.9%
ARGX Sellargenx SEsponsored adr$74,341,830
-31.9%
151,215
-46.0%
0.43%
-32.3%
SWTX  SpringWorks Therapeutics, Inc.$69,356,440
-11.8%
2,999,8460.0%0.40%
-12.1%
KYMR BuyKymera Therapeutics, Inc.$66,030,560
-34.4%
4,750,400
+8.6%
0.38%
-34.5%
IMTX  Immatics N.V.$65,320,649
+0.3%
5,640,8160.0%0.38%
-0.3%
MRTX  Mirati Therapeutics, Inc.$61,410,191
+20.6%
1,409,7840.0%0.35%
+20.0%
KNSA  Kiniksa Pharmaceuticals, Ltd.$48,802,352
+23.4%
2,809,5770.0%0.28%
+22.7%
RARE BuyUltragenyx Pharmaceutical Inc.$48,717,401
+34.9%
1,366,547
+74.5%
0.28%
+34.4%
DNLI BuyDenali Therapeutics Inc.$47,284,022
+10.1%
2,292,003
+57.5%
0.27%
+9.6%
PRLD  Prelude Therapeutics Inc.$31,282,616
-31.3%
10,123,8240.0%0.18%
-31.8%
KOD  Kodiak Sciences Inc.$31,158,882
-73.9%
17,310,4900.0%0.18%
-74.0%
NRIX  Nurix Therapeutics, Inc.$30,513,503
-21.3%
3,882,1250.0%0.18%
-21.4%
BMEA  Biomea Fusion, Inc.$29,019,138
-37.3%
2,108,9490.0%0.17%
-37.7%
IDYA  IDEAYA Biosciences, Inc.$28,656,079
+14.8%
1,062,1230.0%0.16%
+14.6%
CERS BuyCerus Corporation$27,927,992
-29.3%
17,239,501
+7.3%
0.16%
-29.7%
AVTE  Aerovate Therapeutics, Inc.$26,644,410
-20.9%
1,963,4790.0%0.15%
-21.0%
IGMS BuyIGM Biosciences, Inc.$26,367,329
-9.5%
3,157,764
+0.0%
0.15%
-10.1%
XENE  Xenon Pharmaceuticals Inc.$25,675,988
-11.3%
751,6390.0%0.15%
-11.4%
CABA  Cabaletta Bio, Inc.$24,260,680
+17.9%
1,594,0000.0%0.14%
+17.6%
GLUE BuyMonte Rosa Therapeutics, Inc.$23,548,095
+13.7%
4,916,095
+62.6%
0.14%
+13.3%
DBVT  DBV Technologies S.A.sponsored adr$19,875,399
-28.4%
14,614,2640.0%0.12%
-28.6%
KRYS  Krystal Biotech, Inc.$19,712,344
-1.2%
169,9340.0%0.11%
-0.9%
VERV  Verve Therapeutics, Inc.$18,783,188
-29.3%
1,416,5300.0%0.11%
-29.9%
BCYC  Bicycle Therapeutics plcsponsored ads$16,952,223
-21.3%
843,8140.0%0.10%
-21.6%
IMVT NewImmunovant, Inc.$16,316,096425,009
+100.0%
0.09%
COGT BuyCogent Biosciences, Inc.$12,606,419
+8.7%
1,292,966
+32.0%
0.07%
+9.0%
DAWN  Day One Biopharmaceuticals, Inc.$12,270,000
+2.8%
1,000,0000.0%0.07%
+2.9%
 Prime Medicine, Inc.$9,811,566
-34.9%
1,028,4660.0%0.06%
-34.5%
RLAY  Relay Therapeutics, Inc.$9,756,584
-33.0%
1,160,1170.0%0.06%
-33.3%
 2seventy bio, Inc.$9,790,302
-61.3%
2,497,5260.0%0.06%
-61.6%
PACB  Pacific Biosciences of California, Inc.$9,416,980
-37.2%
1,127,7820.0%0.05%
-37.9%
INSM  Insmed Incorporated$8,660,750
+19.7%
343,0000.0%0.05%
+19.0%
ADAP  Adaptimmune Therapeutics plcsponsored adr$8,556,040
-15.7%
10,969,2820.0%0.05%
-16.9%
 Tango Therapeutics, Inc.$8,445,000
+239.2%
750,0000.0%0.05%
+250.0%
HRTX  Heron Therapeutics, Inc.$8,375,628
-11.2%
8,131,6780.0%0.05%
-12.7%
ARVN NewArvinas, Inc.$8,120,767413,481
+100.0%
0.05%
TSHA NewTaysha Gene Therapies, Inc.$7,915,0292,504,756
+100.0%
0.05%
SANA  Sana Biotechnology, Inc.$7,740,000
-35.1%
2,000,0000.0%0.04%
-34.8%
SBTX  ARS Pharmaceuticals, Inc.$7,584,385
-43.6%
2,006,4510.0%0.04%
-43.6%
BLUE  bluebird bio, Inc.$7,599,134
-7.6%
2,499,7150.0%0.04%
-8.3%
 TScan Therapeutics, Inc.$7,129,068
+2.4%
2,784,7920.0%0.04%
+2.5%
NewSagimet Biosciences Inc.$7,175,159815,359
+100.0%
0.04%
GERN  Geron Corporation$6,489,795
-34.0%
3,061,2240.0%0.04%
-35.1%
ATHA  Athira Pharma, Inc.$6,370,690
-31.5%
3,153,8070.0%0.04%
-31.5%
NewInvitae Corporationseries a 4.5% 3/15/2028$6,208,3689,274,000
+100.0%
0.04%
ALEC  Alector, Inc.$6,252,234
+7.8%
964,8510.0%0.04%
+5.9%
EWTX BuyEdgewise Therapeutics, Inc.$6,014,775
+55.2%
1,049,699
+109.9%
0.04%
+59.1%
MIRM NewMirum Pharmaceuticals, Inc.$6,019,042190,476
+100.0%
0.04%
SMMT SellSummit Therapeutics Inc.$5,872,685
-62.9%
3,140,473
-50.2%
0.03%
-63.0%
STOK SellStoke Therapeutics, Inc.$5,854,505
-74.1%
1,485,915
-30.2%
0.03%
-74.0%
HOOK BuyHOOKIPA Pharma Inc.$4,968,285
+27.6%
8,065,398
+82.2%
0.03%
+26.1%
 Aadi Bioscience, Inc.$4,791,252
-29.2%
989,9280.0%0.03%
-28.2%
CELC NewCelcuity Inc.$4,894,269535,478
+100.0%
0.03%
MORF NewMorphic Holding, Inc.$4,943,978215,800
+100.0%
0.03%
NewNeoleukin Therapeutics, Inc.$4,824,5851,221,414
+100.0%
0.03%
OPT SellOpthea Limitedsponsored ads$4,687,532
-37.8%
2,690,891
-0.0%
0.03%
-38.6%
NTRA  Natera, Inc.$4,425,000
-9.1%
100,0000.0%0.03%
-7.1%
DSGN BuyDesign Therapeutics, Inc.$3,540,000
+12.4%
1,500,000
+200.0%
0.02%
+11.1%
PRAX  Praxis Precision Medicines, Inc.$3,214,655
+48.7%
1,879,9150.0%0.02%
+46.2%
CMPX  Compass Therapeutics, Inc.$3,068,531
-38.1%
1,557,6300.0%0.02%
-37.9%
GRCL  Gracell Biotechnologies Inc.sponsored ads$2,880,000
-24.4%
1,000,0000.0%0.02%
-22.7%
SellTalis Biomedical Corporation$2,933,024
-19.9%
508,323
-93.3%
0.02%
-19.0%
SellSera Prognostics, Inc.$2,818,536
-51.9%
1,515,342
-14.7%
0.02%
-52.9%
PCVX  Vaxcyte, Inc.$2,492,157
+2.1%
48,8850.0%0.01%0.0%
BuyKALA BIO, Inc.$2,372,856
+39.9%
266,613
+129.4%
0.01%
+40.0%
XNCR  Xencor, Inc.$2,481,009
-19.3%
123,1270.0%0.01%
-22.2%
IPSC  Century Therapeutics, Inc.$2,298,680
-36.7%
1,149,3400.0%0.01%
-38.1%
ACHL  Achilles Therapeutics plcsponsored ads$2,326,750
-3.7%
2,557,1490.0%0.01%
-7.1%
TIL SellInstil Bio, Inc.$2,013,481
-30.7%
4,704,395
-10.8%
0.01%
-29.4%
ISR BuyPerspective Therapeutics, Inc.$2,090,987
+35.0%
7,639,703
+229.4%
0.01%
+33.3%
AFMD SellAffimed N.V.$2,126,007
-46.1%
4,448,644
-32.6%
0.01%
-47.8%
ANAB SellAnaptysBio, Inc.$1,907,298
-87.9%
106,197
-86.3%
0.01%
-87.9%
PMVP  PMV Pharmaceuticals, Inc.$1,977,227
-1.9%
322,0240.0%0.01%
-8.3%
PNT SellPOINT Biopharma Global Inc.$1,667,287
-84.3%
249,968
-78.6%
0.01%
-83.6%
ALGS  Aligos Therapeutics, Inc.$1,551,071
-23.1%
2,076,4000.0%0.01%
-25.0%
ITOS  iTeos Therapeutics, Inc.$1,646,289
-17.3%
150,3460.0%0.01%
-25.0%
 Leap Therapeutics, Inc.$1,617,602
-55.9%
1,172,1750.0%0.01%
-57.1%
VOR  Vor Biopharma Inc.$1,343,758
-31.4%
633,8480.0%0.01%
-27.3%
MRSN  Mersana Therapeutics, Inc.$1,379,366
-61.4%
1,086,1150.0%0.01%
-61.9%
RNA SellAvidity Biosciences, Inc.$1,061,294
-88.0%
166,347
-79.2%
0.01%
-88.2%
NVTA SellInvitae Corporation$1,067,903
-89.4%
1,764,546
-80.1%
0.01%
-89.7%
BCEL  Atreca, Inc.$922,050
-73.4%
3,532,7600.0%0.01%
-75.0%
GTH  Genetron Holdings Limitedads$369,754
-12.7%
455,3060.0%0.00%0.0%
TARA  Protara Therapeutics, Inc.$333,451
-30.1%
199,6710.0%0.00%
-33.3%
FHTX  Foghorn Therapeutics Inc.$225,135
-29.0%
45,0270.0%0.00%
-50.0%
 Surrozen, Inc.w exp 8/11/2026$34,250
-25.5%
833,3330.0%0.00%
VINC ExitVincerx Pharma, Inc.$0-225,579
-100.0%
-0.00%
NKTX ExitNkarta, Inc.$0-271,329
-100.0%
-0.00%
FGEN ExitFibroGen, Inc.$0-238,084
-100.0%
-0.00%
AGLE ExitAeglea BioTherapeutics, Inc.$0-3,410,106
-100.0%
-0.01%
VERA ExitVera Therapeutics, Inc.cl a$0-146,464
-100.0%
-0.01%
NLTX ExitNeoleukin Therapeutics, Inc.$0-3,821,740
-100.0%
-0.02%
ARAV ExitAravive, Inc.$0-3,261,224
-100.0%
-0.02%
MREO ExitMereo BioPharma Group PLCsponsored ads$0-3,554,979
-100.0%
-0.03%
MGNX ExitMacroGenics, Inc.$0-892,579
-100.0%
-0.03%
ALLO ExitAllogene Therapeutics, Inc.$0-1,576,901
-100.0%
-0.04%
FATE ExitFate Therapeutics, Inc.$0-1,671,717
-100.0%
-0.05%
ExitVerastem, Inc.$0-1,336,485
-100.0%
-0.06%
IMGN ExitImmunoGen, Inc.$0-1,520,097
-100.0%
-0.17%
ExitDICE Therapeutics, Inc.$0-1,035,786
-100.0%
-0.28%
KDNY ExitChinook Therapeutics, Inc.$0-1,455,202
-100.0%
-0.32%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

About Baker Brothers Advisors

Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.

Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.

The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.

Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Incyte Corporation42Q3 202337.6%
ACADIA Pharmaceuticals Inc.42Q3 202310.9%
Biomarin Pharmaceuticals Inc.42Q3 20235.9%
BioCryst Pharmaceuticals, Inc.42Q3 20231.7%
Cerus Corporation42Q3 20230.9%
Insmed Incorporated42Q3 20230.4%
Mirati Therapeutics, Inc.41Q3 20231.8%
Bluebird Bio Inc.41Q3 20230.3%
Heron Therapeutics, Inc.39Q3 20231.5%
ChemoCentryx, Inc.37Q3 20220.6%

View Baker Brothers Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Baker Brothers Advisors Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Neoleukin Therapeutics, Inc.August 17, 20239,469,83820.0%
Mereo Biopharma Group plcAugust 10, 202314,604,3912.2%
Verastem, Inc.August 10, 2023? ?
TScan Therapeutics, Inc.June 02, 20232,793,9386.5%
ACADIA PHARMACEUTICALS INCMay 24, 202343,084,28026.5%
INCYTE CORPMarch 15, 202336,280,96716.3%
Seagen Inc.March 13, 202346,985,65625.1%
Talis Biomedical CorpMarch 10, 202337,569,14066.2%
Aeglea BioTherapeutics, Inc.February 14, 20236,384,0139.9%
Merus N.V.February 14, 2023? ?

View Baker Brothers Advisors's complete significant-ownership history.

Latest filings
TypeFiled
32024-04-01
42024-04-01
42024-04-01
42024-04-01
SC 13D2024-04-01
42024-03-28
SC 13D/A2024-03-28
42024-03-25
SC 13D/A2024-03-25
42024-03-14

View Baker Brothers Advisors's complete filings history.

Compare quarters

Export Baker Brothers Advisors's holdings